XXXX + T-cells in psoriatic lesions preferentially use T-cell receptors V beta 3 and/or V beta 13.1 genes.

@entity1 @entity1569 @entity405 @entity2612 @entity15 @entity792 @entity309
Restricted T-cell receptor V beta gene use in animal models of @entity792 has led to the development of strategies to treat @entity792 by targeting the T-cell receptors of the pathogenic T-cells. Restricted T-cell receptor gene use has been noted in @entity1 @entity792 such as @entity309 and @entity15 . We report here the finding of restricted T-cell receptor gene use in @entity1569 , as well. Our results show an elevated skin (over PBL) expression of V beta 3 and/or V beta 13.1 messages in the @entity405 + T-cells in a majority of @entity1 studied. @entity2612 sequence analysis on these two V beta s from the skin demonstrated monoclonality or marked oligoclonality. A second biopsy performed 3.5 to 8 months later in four @entity1 , at the same or different lesions, again revealed an elevated V beta 3 and/or V beta 13.1 expression and clonality. Moreover, in three of the four @entity1 , the same TcR V beta @entity2612 rearrangement was found in both biopsies, although there was no V beta @entity2612 homology noted between @entity1 . In two @entity1 in which V beta 3 and/or V beta 13.1 was not elevated in the @entity405 + T-cell population, an increase in V beta 17 gene use and clonality was found. The persistence of V beta 3- and/or V beta 13.1-bearing @entity405 + T-cells in lesions that did not undergo resolution suggests their role as effector cells rather than as regulatory cells. The effector function of these @entity405 + T-cells is further supported by the clonality of TcR V beta sequence data, which indicates they are recruited and expanded in situ. The V beta s identified in this study are candidate targets for selective immunotherapeutic intervention in @entity1569 .
